| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US10085958 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2032
(8 years from now) | |
| US9517220 | BAUSCH AND LOMB | Bromfenac bioavailability |
Nov, 2033
(9 years from now) | |
Prolensa is owned by Bausch And Lomb.
Prolensa contains Bromfenac Sodium.
Prolensa has a total of 9 drug patents out of which 6 drug patents have expired.
Expired drug patents of Prolensa are:
- US8754131
- US9561277
- US8927606
- US9144609
- US8669290
- US8871813
Prolensa was authorised for market use on 05 April, 2013.
Prolensa is available in solution/drops;ophthalmic dosage forms.
Prolensa can be used as treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery, method of treating ocular inflammation.
The generics of Prolensa are possible to be released after 11 November, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery; Method of treating ocular inflammation
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
